Sunday, 17 April 2016

Canbex Leaves London

Official Title: A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis


As you can see from clinical trials. gov (NCT02542787). It is now possible to participate in the "Canbex" Trial if you are based outside of London as there are new sites in Liverpool and now in Sheffield. 

Even if you live outside these regions and can travel to them you still may be able to participate, as I understand someone has travelled about 200miles to London

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02542787

Ages Eligible for Study:  18 Years to 70 Years
Genders Eligible for Study:  Both
Accepts Healthy Volunteers:  No

Criteria
Inclusion Criteria:
  • Have a confirmed diagnosis of MS
  • Have an Expanded Disability Status Scale (EDSS) ≤ than 6.5 at screening. 
  • Spasticity due to MS of at least 3 months duration with minimum mean score of >/=2 mASH

Exclusion Criteria:
  • Acute MS relapse requiring treatment with steroids within 30 days of screening.
  • Initiation or discontinuation of MS disease modifying treatment (DMT) within 30 days of screening.
  • Receiving medications that would potentially interfere with the actions of the study medication or outcome variables
  • Significant renal and hepatic abnormalities
  • Previous history of other significant medical disorders

Contacts
Contact: Dr Rachel Farrell 020 3448 3561 rachel.farrell@ucl.ac.uk

The Neuroscience Research Centre, The Walton Centre NHS Foundation Trust Recruiting
Liverpool, United Kingdom, L9 7LJ
Contact: Susan Whittam 0151 529 5666 susan.whittam@thewaltoncentre.nhs.uk
Principal Investigator: Dr Wojciech Pietkiewicz
The Royal London Hospital Recruiting
London, United Kingdom, E1 1BB
Contact: Maria Espasandin 02035940637/8 Maria.Espasandin@bartshealth.nhs.uk
Contact: Kimberley Allen-Philbey 02035941765 Kimberley.Allen-Philbey@bartshealth.nhs.uk
Principal Investigator: Dr Clarence Liu
The National Hospital for Neurology and Neurosurgery Recruiting
London, United Kingdom, WC1N 3BG
Contact: Dr Rachel Farrell
Contact: Michelle Liddicut Michelle.Liddicut@uclh.nhs.uk
Principal Investigator: Dr Rachel Farrell
Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust Recruiting
Sheffield, United Kingdom, S10 2JFS
Contact: Kamel Bouakline 0114 271 3339 kamel.bouakline@sth.nhs.uk
Principal Investigator: Dr Siva Nair

CoI:  We are founders of Canbex who are developing VSN16

1 comment:

  1. Wow, the problem is that I live on another continent it is certainly not participate in the trial, because still practice physical activity and would like to see the results of VSN 16R as possible spasticity post workout and cramps ...

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.